MXPA03009482A - Compuestos triciclicos utiles como inhibidores de la transcriptasa inversa del virus de inmunodeficiencia humana (vih). - Google Patents

Compuestos triciclicos utiles como inhibidores de la transcriptasa inversa del virus de inmunodeficiencia humana (vih).

Info

Publication number
MXPA03009482A
MXPA03009482A MXPA03009482A MXPA03009482A MXPA03009482A MX PA03009482 A MXPA03009482 A MX PA03009482A MX PA03009482 A MXPA03009482 A MX PA03009482A MX PA03009482 A MXPA03009482 A MX PA03009482A MX PA03009482 A MXPA03009482 A MX PA03009482A
Authority
MX
Mexico
Prior art keywords
reverse transcriptase
compounds useful
transcriptase inhibitors
hiv reverse
tricyclic compounds
Prior art date
Application number
MXPA03009482A
Other languages
English (en)
Inventor
Barry L Johnson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA03009482A publication Critical patent/MXPA03009482A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
MXPA03009482A 2001-04-19 2002-04-17 Compuestos triciclicos utiles como inhibidores de la transcriptasa inversa del virus de inmunodeficiencia humana (vih). MXPA03009482A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28481801P 2001-04-19 2001-04-19
PCT/US2002/012208 WO2002085365A1 (en) 2001-04-19 2002-04-17 Tricyclic compounds useful as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
MXPA03009482A true MXPA03009482A (es) 2004-02-12

Family

ID=23091633

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009482A MXPA03009482A (es) 2001-04-19 2002-04-17 Compuestos triciclicos utiles como inhibidores de la transcriptasa inversa del virus de inmunodeficiencia humana (vih).

Country Status (10)

Country Link
US (1) US6825210B2 (es)
EP (1) EP1379248A1 (es)
JP (1) JP2004532224A (es)
CN (1) CN1649591A (es)
AR (1) AR033702A1 (es)
BR (1) BR0208987A (es)
CA (1) CA2444570A1 (es)
HU (1) HUP0303818A2 (es)
MX (1) MXPA03009482A (es)
WO (1) WO2002085365A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041020A1 (en) * 1995-06-07 1996-12-19 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
US7118859B2 (en) * 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US7858298B1 (en) * 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
AU2004273773B2 (en) * 2003-02-21 2008-01-24 Jarrow Formulas, Inc. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
AU2006272750B2 (en) * 2005-07-22 2011-09-29 Cytodyn, Inc. Methods for reducing viral load in HIV-1-infected patients
EP2174344A4 (en) * 2007-07-13 2012-06-20 Intermolecular Inc SURFACE MODIFICATION OF LOW-K DIELECTRIC MATERIALS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0065392B1 (en) 1981-05-13 1985-02-13 Imperial Chemical Industries Plc Pharmaceutical compositions containing spiro succinimide derivatives
US5171745A (en) 1990-07-13 1992-12-15 Du Pont Merck Pharmaceutical Company Method of treating neurological dysfunction using neutrotransmitter enhancers
IL102764A0 (en) 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
AU2436792A (en) 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
WO1993020080A1 (en) 1992-03-27 1993-10-14 Schering Corporation Bridged bis-aryl carbinol derivatives, compositions and methods of use
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
CA2145407C (en) 1992-09-28 2009-09-22 Louis A. Carpino New reagents for peptide couplings
US5594001A (en) 1993-04-08 1997-01-14 The Dupont Merck Pharmaceutical Company Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
DE4320347A1 (de) 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
AU1046895A (en) 1993-11-05 1995-05-23 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5750528A (en) 1995-02-01 1998-05-12 The Dupont Merck Pharmaceutical Company Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease
AU5270796A (en) 1995-04-07 1996-10-23 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters th ereof
US5874430A (en) 1996-10-02 1999-02-23 Dupont Pharmaceuticals Company 4,4-disubstitued-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same
US6124302A (en) 1997-04-09 2000-09-26 Dupont Pharmaceuticals 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
AU4719799A (en) * 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
US6593337B1 (en) * 1999-10-19 2003-07-15 Bristol-Myers Squibb Pharma Company Tricyclic compounds useful as HIV reverse transcriptase inhibitors

Also Published As

Publication number Publication date
JP2004532224A (ja) 2004-10-21
HUP0303818A2 (hu) 2004-03-01
CN1649591A (zh) 2005-08-03
BR0208987A (pt) 2004-04-27
AR033702A1 (es) 2004-01-07
US6825210B2 (en) 2004-11-30
EP1379248A1 (en) 2004-01-14
US20020177603A1 (en) 2002-11-28
WO2002085365A1 (en) 2002-10-31
CA2444570A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
IL149219A0 (en) Tricyclic compounds useful as hiv reverse transcriptase inhibitors
HUS2200038I1 (hu) HIV-gátló pirimidinszármazékok
ZA200306549B (en) Benzophenones as inhibitors of reverse transcriptase.
MXPA03007160A (es) Composicion de aceite base lubricante.
MXPA03008144A (es) Nuevos compuestos antiinflamatorios de triazolopiridinas.
EP1549315A4 (en) DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
AP2005003366A0 (en) Pyrimidine derivatives for the prevention of HIV infection.
AU2002328092A1 (en) Bicyclic compound, production and use as hiv inhibitors
HK1054034A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors.
DE60215854D1 (de) Rückwärtsfahrende Sperrkupplung
MXPA03007310A (es) Derivados de ftalazinona piperidino como inhibidores pde4.
MXPA03009361A (es) Compuestos de urea utilies como agentes anti-inflamatorios.
HK1111155A1 (en) Non-nucleoside reverse transcriptase inhibitors
AP2005003451A0 (en) HIV integrase inhibitors.
MXPA03009482A (es) Compuestos triciclicos utiles como inhibidores de la transcriptasa inversa del virus de inmunodeficiencia humana (vih).
MXPA03007693A (es) Composicion para la piel.
PL371418A1 (en) Tricyclic 2-pyrimidone compounds useful as hiv reverse transcriptase inhibitors
AU2003243765A8 (en) 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
EG23378A (en) Composition.
PL365958A1 (en) Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors
EG23284A (en) Plasterboard.
MXPA03008077A (es) Composicion humedecedora para la piel..
MXPA03004534A (es) Compuestos novedosos para su uso como inhibidores de la proteasa del virus de inmunodeficiencia humana (vih).
AU5588400A (en) 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.